HomeCompareEMSH vs JNJ

EMSH vs JNJ: Dividend Comparison 2026

EMSH yields 3.09% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMSH wins by $4.4K in total portfolio value
10 years
EMSH
EMSH
● Live price
3.09%
Share price
$64.73
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.4K
Annual income
$376.99
Full EMSH calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — EMSH vs JNJ

📍 EMSH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMSHJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMSH + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMSH pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMSH
Annual income on $10K today (after 15% tax)
$262.62/yr
After 10yr DRIP, annual income (after tax)
$320.44/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $383.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMSH + JNJ for your $10,000?

EMSH: 50%JNJ: 50%
100% JNJ50/50100% EMSH
Portfolio after 10yr
$22.2K
Annual income
$602.39/yr
Blended yield
2.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EMSH
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMSH buys
0
JNJ buys
0
No recent congressional trades found for EMSH or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMSHJNJ
Forward yield3.09%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$24.4K$20.0K
Annual income after 10y$376.99$827.78
Total dividends collected$3.5K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EMSH vs JNJ ($10,000, DRIP)

YearEMSH PortfolioEMSH Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,009$308.96$10,676$355.77+$333.00EMSH
2$12,097$317.88$11,407$389.39+$690.00EMSH
3$13,271$326.46$12,198$426.53+$1.1KEMSH
4$14,534$334.69$13,056$467.62+$1.5KEMSH
5$15,894$342.58$13,987$513.12+$1.9KEMSH
6$17,357$350.13$14,998$563.56+$2.4KEMSH
7$18,929$357.34$16,098$619.52+$2.8KEMSH
8$20,619$364.21$17,295$681.69+$3.3KEMSH
9$22,433$370.76$18,599$750.82+$3.8KEMSH
10$24,380$376.99$20,022$827.78+$4.4KEMSH

EMSH vs JNJ: Complete Analysis 2026

EMSHStock

The index is comprised of a diversified portfolio of USD-denominated Emerging Market bonds that have less than or equal to five years remaining to maturity that are issued by Emerging Market sovereign governments, non-sovereign government agencies and entities, and corporations with significant government ownership. The fund will invest in U.S. dollar-denominated debt instruments issued by Sovereign, Sub-Sovereign or Quasi-Sovereign issuers.

Full EMSH Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this EMSH vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMSH vs SCHDEMSH vs JEPIEMSH vs OEMSH vs KOEMSH vs MAINEMSH vs ABBVEMSH vs MRKEMSH vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.